Liver Cirrhosis - Drug Pipeline Landscape, 2023

Liver Cirrhosis - Drug Pipeline Landscape, 2023

Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known as fibrosis as a result of liver disease damage.

Cirrhosis is caused by alcoholic liver disease, non-alcoholic steatohepatitis (NASH), heroin abuse, chronic hepatitis B, and chronic hepatitis C.

Cirrhosis symptoms emerge slowly until liver damage is extensive. Signs and symptoms include tiredness, weakness, loss of appetite, weight loss, and nausea.

Cirrhosis is initially detected through a routine blood test. The other tests, including magnetic resonance elastography (MRE), MRI, CT, and ultrasound, are recommended. To identify the severity, extent, and cause of liver damage, a biopsy is preferred.

The goal of cirrhosis treatment is to slow or prevent the worsening of the condition. A healthy diet is recommended, consisting of a high-protein, high-fiber diet plus supplementation with branched-chain amino acids. Antibiotics are recommended for infections; other medications include carvedilol. Liver transplantation is recommended in cases of uncontrolled conditions.

Report Highlights

Global Insight Service’s, Liver Cirrhosis - Drug Pipeline Landscape, 2023 report provides an overview of the Liver Cirrhosis pipeline drugs. This report covers detailed insights on Liver Cirrhosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Liver Cirrhosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.